Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Everest Medicines Signs $61.5 Million Deal for Drug Resistant Antibiotic

publication date: Jan 9, 2019

Everest Medicines, a Shanghai in-licensing company, acquired greater China rights to a multi-drug resistant, gram negative antibiotic from Spero Therapeutics in an agreement worth up to $61.5 million. Everest will pay $2 million upfront and as much as $59.5 million in milestones, plus royalties on sales. It will also have an option on a similar deal for a second Spero MDR IV antibiotic. A two-year-old company, Everest is backed by $50 million in initial financing led by China's C-Bridge Capital. More details....

Stock Symbol: (NSDQ: SPRO)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events


China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020